BARD1 Life Sciences Limited (ASX:BD1)
BARD1 Life Sciences Ltd (ASX:BD1) is an Australian life sciences company developing novel diagnostics and therapeutics for unmet needs in cancer. Its proprietary BARD1 Technology is based on BARD1, a potent tumour suppressor in healthy individuals and important tumour biomarker in cancer. Its lead product the BARD1 Lung Cancer Test is a non-invasive blood test in development for early detection of lung cancer.
Top Results: BD1 Continues to Boost its Ovarian Cancer Detection Studies
May 21, 2018
BARD1 Life Sciences Limited (ASX:BD1) has both lung and ovarian cancer in its sights.
Related BARD1 Life Sciences Limited (ASX:BD1) articles
Beating Cancer via Early Detection: ASX Stock Targeting Multiple Billion Dollar Markets
Apr 4, 2017
If you are going to beat cancer, your best bet is to catch it early. Of course, that’s easier said than done. By the time the symptoms of many cancers are apparent, a patient is often already in late stages of the disease. This is particularly true for lung cancer.
Is JAT’s First $10M in Sales a Stepping Stone to the Trillion Dollar China Retail Market?
Oct 18, 2018
Canada Legalises Cannabis as CPH Moves Front and Centre With a 100% Owned Canadian Growing Facility
Oct 18, 2018